European Commission launches proposals for first Joint Technology Initiatives

The European Commission is now on the road to creating the first ever Europe-wide public-private partnerships to boost research and development, having adopted proposals for initiatives in two strategic industrial sectors.

The Commission presented two Joint Technology Initiatives (JTIs), worth approximately €5 billion, on embedded computing systems, to be known as ARTEMIS (Advanced Research and Technology for Embedded Intelligence and Systems), and on innovative medicines (Innovative Medicines Initiative).

The two JTIs will pool private sector investment with national and European public funding to create a single European-wide research programme that is driven by the needs of industry, and focused on clear joint technological and economic objectives.

"Europe needs a new approach to research in promising areas for our competitiveness and well-being," said EU Science and Research Commissioner Janez Potocnik.

"The proposals today show that the European Commission is committed to thinking differently where that is what Europe needs."

The novel JTIs will move away from the traditional approach of case-by-case public funding of projects, and head towards large scale research programmes dedicated to meeting the common strategic research targets of specific industrial sectors.

The European Commission hopes that the new bottom-up approach will stimulate European investment in research and development and build critical mass by uniting currently fragmented efforts.

ARTEMIS, will address the invisible technology (embedded systems) found in many machines today, ranging from cars, planes and mobile phones, energy networks and factories to washing machines and televisions.

Its research budget will total €2.7 billion over seven years, with around 60% of the budget expected to come from industry, €410 million from the Commission and €800 million from EU Member States.

The Innovative Medicines Initiative (IMI) will aim to support the development of new knowledge, tools and methods so that better and safer medicines can be made available on the market more quickly.

This programme will have €2 billion to invest over seven years. The Community contribution of ¿1 billion will go entirely to small and medium-sized enterprises (SMEs) and universities, for research that can be used by the pharmaceutical sector. In return, major companies will match this amount and involve these same SMEs and universities. The IMI will therefore contribute to increasing private investment in R&D, improving knowledge transfer between universities and business, and involving small business in European research.

Although there are substantial levels of public funding involved in JTIs, the Commission insists that the new research initiatives are designed to be as administratively fast, flexible and light as possible, with overheads being as low as between 1.5 and 4% of the total budget.

Also, the initiatives will be implemented through Joint Undertakings that will be established by Council Regulations on the basis of Article 171 of the EC Treaty.

Mr Potocnik said: "Each JTI will be managed by a Joint Undertaking, funded by both industry and the public sector (European and/or national). They will be established under Community law, a first for an organisation of this type. We have designed them to have the necessary flexibility to function as private/public partnerships while guaranteeing a sound implementation of Community funds."

The Commission's proposals for each JTI will be presented to the Competitiveness Council on 21 and 22 May, with the hope that the regulations will be adopted during the Portuguese Presidency, in time for both JTIs to start work early in 2008.

The next potential candidates for JTIs are in the fields of nano-electronics, clean skies (greening of aeronautics), hydrogen and fuel cells, and global monitoring for environment and security. Proposals are expected to follow soon.

"I don't think I can emphasise enough that what we are proposing today is truly ground-breaking. Seeing this through will require real commitment from all those involved: industry, Commission, Member States, European Parliament. It may not always be easy. But it is too important not to try, and not to give it everything we've got," the Commissioner concluded.

For further information, please visit:

Copyright ©European Communities, 2007
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Most Advanced Artificial Touch for Brain…

For the first time ever, a complex sense of touch for individuals living with spinal cord injuries is a step closer to reality. A new study published in Science, paves...

Predicting the Progression of Autoimmune…

Autoimmune diseases, where the immune system mistakenly attacks the body's own healthy cells and tissues, often have a preclinical stage before diagnosis that’s characterized by mild symptoms or certain antibodies...

Major EU Project to Investigate Societal…

A new €3 million EU research project led by University College Dublin (UCD) Centre for Digital Policy will explore the benefits and risks of Artificial Intelligence (AI) from a societal...

New AI Tool Uses Routine Blood Tests to …

Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will benefit from immune checkpoint inhibitors - a type of...

Using AI to Uncover Hospital Patients�…

Across the United States, no hospital is the same. Equipment, staffing, technical capabilities, and patient populations can all differ. So, while the profiles developed for people with common conditions may...

New Method Tracks the 'Learning Cur…

Introducing Annotatability - a powerful new framework to address a major challenge in biological research by examining how artificial neural networks learn to label genomic data. Genomic datasets often contain...

Picking the Right Doctor? AI could Help

Years ago, as she sat in waiting rooms, Maytal Saar-Tsechansky began to wonder how people chose a good doctor when they had no way of knowing a doctor's track record...

From Text to Structured Information Secu…

Artificial intelligence (AI) and above all large language models (LLMs), which also form the basis for ChatGPT, are increasingly in demand in hospitals. However, patient data must always be protected...

AI Innovation Unlocks Non-Surgical Way t…

Researchers have developed an artificial intelligence (AI) model to detect the spread of metastatic brain cancer using MRI scans, offering insights into patients’ cancer without aggressive surgery. The proof-of-concept study, co-led...

Deep Learning Model Helps Detect Lung Tu…

A new deep learning model shows promise in detecting and segmenting lung tumors, according to a study published in Radiology, a journal of the Radiological Society of North America (RSNA)...

New Study Reveals AI's Transformati…

Intensive care units (ICUs) face mounting pressure to effectively manage resources while delivering optimal patient care. Groundbreaking research published in the INFORMS journal Information Systems Research highlights how a novel...

One of the Largest Global Surveys of Soc…

As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch...